Literature DB >> 24549861

The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations.

S Köhler1, S Gaus1, T Bschor2.   

Abstract

Bipolar depression and its clinical presentation is a frequent but complex psychiatric disease. Despite the high prevalence and the clinical and economic relevance of bipolar depression, few treatments are proven to be highly and consistently effective. In practice, the treatment of bipolar depression typically includes complex treatment decision-making. The best evidence for a pharmacological treatment exists for quetiapine. Alternatives with limitations are lamotrigine (also in the combination with lithium), carbamazepine and olanzapine. The effectiveness and recommendation of antidepressants in the treatment of bipolar depression remains controversial. Initially, depressive episodes should been treated with one of the named substances with antidepressant properties. In non-responders, a combination of lithium and lamotrigine, or antidepressants in combination with either lithium, an antiepileptic drug or atypical antipsychotics, may be necessary. If a depressive episode occurs under ongoing mood-stabilizing treatment, combination treatments of different substances, even with antidepressants, can be necessary. In the case of treatment-resistant depressive episodes, complex treatment strategies (combination therapies, MAO inhibitors) should be considered. This review describes the treatment recommendations of different guidelines for bipolar depression and emphasizes their differences. Furthermore, alternative pharmacological treatment strategies and complex treatment situations are discussed. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24549861     DOI: 10.1055/s-0033-1364004

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

1.  50 Useful Sociodemographic and Clinical Tips to Overcome the Challenge Differentiating Bipolar Depression from Unipolar Depression.

Authors:  Halil Ozcan; Ugur Takim
Journal:  Eurasian J Med       Date:  2021-02

Review 2.  [German S3 guidelines on bipolar disorders-first update 2019 : What is new in pharmacotherapy?]

Authors:  T Bschor; C Baethge; H Grunze; U Lewitzka; H Scherk; E Severus; M Bauer
Journal:  Nervenarzt       Date:  2020-03       Impact factor: 1.214

Review 3.  Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder.

Authors:  Jose de Leon; Edoardo Spina
Journal:  Curr Psychiatry Rep       Date:  2018-03-12       Impact factor: 5.285

Review 4.  The significance of mixed states in depression and mania.

Authors:  Giulio Perugi; Giuseppe Quaranta; Liliana Dell'Osso
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

5.  A cluster analytic approach to identifying predictors and moderators of psychosocial treatment for bipolar depression: Results from STEP-BD.

Authors:  Thilo Deckersbach; Amy T Peters; Louisa G Sylvia; Alexandra K Gold; Pedro Vieira da Silva Magalhaes; David B Henry; Ellen Frank; Michael W Otto; Michael Berk; Darin D Dougherty; Andrew A Nierenberg; David J Miklowitz
Journal:  J Affect Disord       Date:  2016-05-31       Impact factor: 4.839

Review 6.  Lithium in the treatment of major depressive disorder.

Authors:  Tom Bschor
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 7.  Lithium Treatment Over the Lifespan in Bipolar Disorders.

Authors:  Constantin Volkmann; Tom Bschor; Stephan Köhler
Journal:  Front Psychiatry       Date:  2020-05-07       Impact factor: 4.157

8.  A Pilot Study of Safety and Efficacy of Cranial Electrotherapy Stimulation in Treatment of Bipolar II Depression.

Authors:  Deimante McClure; Samantha C Greenman; Siva Sundeep Koppolu; Maria Varvara; Zimri S Yaseen; Igor I Galynker
Journal:  J Nerv Ment Dis       Date:  2015-11       Impact factor: 2.254

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.